{"id":833174,"date":"2025-04-02T16:06:48","date_gmt":"2025-04-02T20:06:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/"},"modified":"2025-04-02T16:06:48","modified_gmt":"2025-04-02T20:06:48","slug":"enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/","title":{"rendered":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">BOULDER, Colo.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place <span class=\"xn-chron\">April 25-30, 2025<\/span>, in <span class=\"xn-location\">Chicago, Illinois<\/span>.<\/p>\n<p>\n        <b>Poster Presentation Details<\/b>\u00a0<\/p>\n<p>\n        <b>Abstract 4712 \u2013 ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates<\/b><br \/>\n        <br \/>\n        <b>Date\/Time:<\/b><br \/>\n        <span class=\"xn-chron\">Tuesday, April 29, 2025<\/span>, <span class=\"xn-chron\">9:00 a.m.<\/span> \u2013 <span class=\"xn-chron\">12:00 p.m. CDT<\/span><br \/><b>Session: <\/b>Targeted Therapies and Combinations 2<br \/><b>Location:<\/b>\u00a0Poster Section 34<\/p>\n<p>\n        <b>Abstract 4361 \u2013 Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitors<br \/><\/b><br \/>\n        <b>Date\/Time:<\/b><br \/>\n        <span class=\"xn-chron\">Tuesday, April 29, 2025<\/span>, <span class=\"xn-chron\">9:00 a.m.<\/span> \u2013 <span class=\"xn-chron\">12:00 p.m. CDT<\/span><br \/><b>Session:<\/b> Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics<br \/><b>Location:<\/b>\u00a0Poster Section 20<\/p>\n<p>\n        <b>Abstract LB295 \u2013 ELV-3111, a type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistance<br \/><\/b><br \/>\n        <b>Date\/Time:<\/b><br \/>\n        <span class=\"xn-chron\">Tuesday, April 29, 2025<\/span>, <span class=\"xn-chron\">9:00 a.m.<\/span> \u2013 <span class=\"xn-chron\">12:00 p.m. CDT<\/span><br \/><b>Session:<\/b> Late-Breaking Research: Experimental and Molecular Therapeutics 3<br \/><b>Location:<\/b> Poster Section 52<\/p>\n<p>\n        <b>Abstract LB294 \u2013 Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitor<br \/><\/b><br \/>\n        <b>Date\/Time:<\/b><br \/>\n        <span class=\"xn-chron\">Tuesday, April 29, 2025<\/span>, <span class=\"xn-chron\">9:00 a.m.<\/span> \u2013 <span class=\"xn-chron\">12:00 p.m. CDT<\/span><br \/><b>Session:<\/b> Late-Breaking Research: Experimental and Molecular Therapeutics 3<br \/><b>Location:<\/b> Poster Section 52<\/p>\n<p>\n        <b>Abstract 5515 \u2013 ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib<\/b><br \/>\n        <br \/>\n        <b>Date\/Time:<\/b><br \/>\n        <span class=\"xn-chron\">Tuesday, April 29, 2025<\/span>, <span class=\"xn-chron\">2:00 p.m.<\/span> \u2013 <span class=\"xn-chron\">5:00 p.m. CDT<\/span><br \/><b>Session: <\/b>Drug Resistance in Molecular Targeted Therapies 3<br \/><b>Location:<\/b>\u00a0Poster Section 17<\/p>\n<p>Abstracts are currently available on the AACR <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397531-1&amp;h=387778337&amp;u=https%3A%2F%2Fwww.aacr.org%2Fmeeting%2Faacr-annual-meeting-2025%2F&amp;a=website\" target=\"_blank\" rel=\"nofollow\">website<\/a>. Following the presentations, copies will be available on the &#8220;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397531-1&amp;h=4097926430&amp;u=https%3A%2F%2Fwww.enliventherapeutics.com%2Fpipeline%2F%23pubs&amp;a=Program+Presentations+%26+Publications\" target=\"_blank\" rel=\"nofollow\">Program Presentations &amp; Publications<\/a>&#8221; section of the Company&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397531-1&amp;h=4107705376&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DcWbV2eSS8MrEzNOKJNuJ_GG3Jz0Qe8h1KGcHt_FowKPLlw_Dt7TBoxfzEdVDAOANN0GcoxDrRtPVslaPyochHegeNstUG3yRVGJHBizV69OdfsWRB47Gusng79eaVHL7&amp;a=www.enliventherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.enliventherapeutics.com<\/a>.<\/p>\n<p>\n        <b>About\u00a0Enliven Therapeutics<br \/><\/b>Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven&#8217;s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in\u00a0Boulder, <span class=\"xn-location\">Colorado<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3336\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg\" title=\"Enliven Logo (PRNewsfoto\/Enliven Therapeutics, Inc.)\" alt=\"Enliven Logo (PRNewsfoto\/Enliven Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA56314&amp;sd=2025-04-02\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-302419011.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-302419011.html<\/a><\/p>\n<p>SOURCE  Enliven Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA56314&amp;Transmission_Id=202504021603PR_NEWS_USPR_____LA56314&amp;DateId=20250402\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BOULDER, Colo. , April 2, 2025 \/PRNewswire\/ &#8212; Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details\u00a0 Abstract 4712 \u2013 ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date\/Time: Tuesday, April 29, 2025, 9:00 a.m. \u2013 12:00 p.m. CDTSession: Targeted Therapies and Combinations 2Location:\u00a0Poster Section 34 Abstract 4361 \u2013 Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-833174","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOULDER, Colo. , April 2, 2025 \/PRNewswire\/ &#8212; Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details\u00a0 Abstract 4712 \u2013 ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date\/Time: Tuesday, April 29, 2025, 9:00 a.m. \u2013 12:00 p.m. CDTSession: Targeted Therapies and Combinations 2Location:\u00a0Poster Section 34 Abstract 4361 \u2013 Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model &hellip; Continue reading &quot;Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T20:06:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting\",\"datePublished\":\"2025-04-02T20:06:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/\",\"name\":\"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"datePublished\":\"2025-04-02T20:06:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk","og_description":"PR Newswire BOULDER, Colo. , April 2, 2025 \/PRNewswire\/ &#8212; Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details\u00a0 Abstract 4712 \u2013 ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date\/Time: Tuesday, April 29, 2025, 9:00 a.m. \u2013 12:00 p.m. CDTSession: Targeted Therapies and Combinations 2Location:\u00a0Poster Section 34 Abstract 4361 \u2013 Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model &hellip; Continue reading \"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T20:06:48+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting","datePublished":"2025-04-02T20:06:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/","name":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","datePublished":"2025-04-02T20:06:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=833174"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833174\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=833174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=833174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=833174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}